Heartbeam, Inc. Common Stock 2026 Q2 Earnings Call

Good afternoon, everyone, and thank you for taking the time. I know your schedules are very busy. We have a nice tight presentation to provide for you and the agenda, as you can see. I will walk through those elements, the core technology, our highlights, heart attack detection, our initial commercial launch, and the financials. If we go to the next slide. Are we on the next, we're on the next slide?

Yeah, we are. Yeah, just if you could, because I can't see whether or not we've moved to the next slide.

Just let me know that, okay, that slide is up. As you can see from this slide, this to me really frames what really gets all of us at HeartBeam incredibly excited is the fact that every 40 seconds someone suffers from a heart attack. Our technology, which is utilizing TriCor signal capturing technology, is the only true way to evaluate the real extent of that trauma. To reach as many of these patients as possible, we've developed and tested three different form factors, each with a unique approach. As you already know, the card fits into the post-discharge space where many patients, we feel, will find comfort knowing they have a way to monitor their heart health.

The patch fits into the emergency room workflow and in-hospital monitoring of at-risk cardiac patients, greatly reducing the time required to obtain a medical-grade 12-lead EKG and have that information ready to read in near real-time. The HeartBeam remote unit which fits the needs of a device that patients can have access to in remote locations. I will touch base a little bit more as we go through the presentation on this. As you can see, the card is on the far left, and this particular form factor is just simply ideal for the post-discharge monitoring. That is, patients that leave the hospital and need some way to feel some peace of mind at home, in which they feel something, they can take a reading, they have near-time response to that via the 24-hour reading service, and they can have something that's actionable.

They can determine what they need to do via that reading from the physician. The on-demand patch is probably the most exciting form factor from my perspective. This is a device that has extended monitoring with an on-demand 12-lead capability. So it covers two things, 24-hour monitoring, as well as, once again, two fingers on those two electrodes, north and south, that you see in that picture, and you get a medical-grade 12-lead EKG. We will be positioning this device for emergency room departments and post-procedure in-hospital monitoring. For example, patients that go into the hospital that have an ablation procedure, that came into the emergency room having a myocardial infarction, someone that's had cardiac surgery, someone that's had received stents. Many of these patients are held in the hospital for a day or two and then moved to a step-down unit.

Just imagine the fact that all they would need to do is have a patch, and literally the nurse or the physician can just ask the patient to put two fingers onto those electrodes, and they would get in near real-time a true 12-lead EKG reading. This fits into the workflow and eliminates a lot of time that finding an EKG tech to come up from a floor, put on the sticky devices and so forth. We see this as just completely disrupting really the entire space. You have heard us talk about the HeartBeam remote unit. This is a form factor, again, using all the same technology. This is the form factor that we are currently using over in Indonesia, and we will touch base on that, so that we can get patients almost anywhere where they are access and an understanding of what is going on with their heart health.

Next slide, please. Okay. Yep, I have it. If we look at the HeartBeam core technology and platform, every medical device company spends a great deal of time building a moat around their intellectual property. Well, that is exactly what HeartBeam has been doing. We now have 25 issued patents worldwide that are incorporating our proprietary technology, the TriCor 3D signal reconstruction. Essentially, we have the single best signal-capturing device for the interrogation of an EKG signal. That provides us with enormous opportunities to change the way patients will be interfacing with their physicians and their own personal cardiac health. As I think most of you know, this has been clinically validated. We have run numerous studies, which I will touch on before. The FDA has cleared us for arrhythmic assessment, and the body of evidence supporting expansion into heart attack detection and future indications is currently going on.

I will also touch base in a minute on where we are with that initiative. We have now done hundreds and hundreds and hundreds of patients using our current technology. We do not see it as a product. Of course, we see what we are doing as a platform because you can see that the technology is embedded into three different form factors. This opportunity addresses a fundamental gap in the care by providing clinical-grade 12-lead EKGs through multiple form factors. There is just no other technology that we are aware of that does exactly what we are doing. We have designed it, again, this architecture that we are using to enable our card to be used in the patch. Excuse me, not the card, but to have our technology used in the card, the patch, and then in the HeartBeam remote. Next slide. If you look at those key strategic priorities, top of the heap for us is heart attack detection.

We are rapidly advancing the initiatives around the indication for heart attack detection. We have clinical validation efforts are ahead of schedule in terms of this particular initiative. You notice on this slide, we have the pre-sub submitted to the FDA imminently. Well, I am happy to tell you that we actually did submit the pre-sub today, and we are developing additional go-to-market and reimbursement approaches as we are working through the FDA to get approval for the heart attack detection. This will, again, revolutionize how patients, physicians, and hospitals are looking at cardiac health. You also know that we began initial commercial launch.

That is underway, and I think you might recall that the first half of the year, we've referenced the fact that this was our learning stage and that the second half of the year, we would be beginning to gain momentum in generating revenue. Well, that's exactly what we are doing. We are generating real-world deployment evidence with positive feedback from physicians and patients, and I'll touch base on that in just a minute. That is creating a strong foundation for accelerated growth. The concierge vertical for us is a very nice vertical. There is a real need there. There are many patients, almost 2 million patients embedded into concierge services, in which many of them are at-risk cardiac patients, and the physicians and the patients are looking for something that provides them with peace of mind and real-time interpretation of the cardiac health.

The integrated network partnerships. This is something that I mentioned some weeks ago, that this is where we are reaching out to large integrated networks to work with them and run pilots to see how our technology would be incorporated into their workflow. The two workflows that are of particular interest, obviously, is the emergency room department when patients come in feeling chest pain. How can we implement our technology in that setting? Then the setting where patients have had a post-procedure and they remain in the hospital under observation. How best can we utilize our technology in those settings? These integrated networks, as you're well known, have an enormous number of patients. One of the ones that we're talking to has 50 million visits a year, and that's not to the emergency room.